• トップ
  • 日本株
  • 米国株
  • FX・為替
  • 投資信託
  • ニュース
  • 掲示板
  • 証券会社比較
  • 不動産投資
  • NISA
  • カードローン比較
  • 掲示板トップ

ポートフォリオ

ポートフォリオとは?

ポートフォリオはありません

ログインしてポートフォリオを表示

    • トップ
    • 掲示板
    • 検索
    • (株)スリー・ディー・マトリックス【7…
    • GX MSCIガバナンス・クオリティ-…
    • (株)バローホールディングス【9956】
    • (株)アクリート【4395】
    • MAXIS 米国株式(S&P500)上…

    検索結果

    • スレッド
    • コメント
    • 最新の投稿順
    • 古い投稿順
    • 4件中 1件 - 4件を表示
      • 医薬品>
      • ステラファーマ(株)

      さて、TAEと言えば、ちょっと…

      切山椒が好き

      2026/11/18 14:40

      さて、TAEと言えば、ちょっと気になるところがありまして: TAE Life Sciences (TLS) is a medical technology company spun out from TAE Technologies in 2017 that develops next-generation Boron Neutron Capture Therapy (BNCT) for difficult-to-treat and refractory cancers. Key Technologies & Developments • Alphabeam™ Neutron System (ANS): A compact, hospital-installable accelerator-based neutron source derived from TAE's particle accelerator fusion technology. • Proprietary Boron Drugs: • TDP-747: Small-molecule boron drugs offering a much higher tumor-to-healthy boron ratio compared to older compounds like BPA. • Antibody Boron Conjugates (ABCs): Uses Boron Enriched Linkers (BELs) to carry up to 400 boron atoms per antibody. • Biodegradable Nanoparticles: Mesoporous organosilica nanoparticles (BPMOs) for targeted delivery. • Partnerships & Expansion: Partnered with ステラファーマ株式会社 for BNCT drug development and sales in North America and Europe, and announced a contract manufacturing partnership with Foxsemicon Integrated Technology (FITI) for the Alphabeam system. --- 旧来の古いBPAとは大違いの凄いボロン製剤!? こりゃ、やっぱステラファーマも次世代、次々世代、次々々世代のBNCT製剤開発を加速して行かないとね。

      • (米国)医療関連>
      • ハートフロー

      Gross margin wa…

      shi*****

      2026/11/13 07:34

      Gross margin was 83.6%, compared to 76.5% in the prior year period. Non-GAAP gross margin was 83.8%, compared to 76.8% in the prior year period. The year-over-year gross margin expansion was primarily attributable to an increase in total revenue case volume, an increase in total U.S. Plaque revenue case volume, and improved production team productivity driven by AI efficiency initiatives, partially offset by the hiring and training of production team personnel. Gross Marginも改善。いわゆる『数の経済』ですね。売り上げのびてGross Margin改善してて、無理なく黒字が見込めるパターン。

      • 電気機器>
      • キオクシアホールディングス(株)

      S outh Korean c…

      037*****

      2026/10/28 08:42

      S outh Korean chipmaker SK Hynix on Wednesday released its third-quarter earnings results, reporting revenue and operating profit for the July-to-September period. Here are SK Hynix’s third-quarter results compared with LSEG SmartEstimates, which are weighted toward forecasts from analysts who are more consistently accurate: Revenue: 104.62 trillion won vs. 98.34 trillion won expected Operating profit: 83.33 trillion won vs. 76.72 trillion won expected Revenue rose 327.9% from a year earlier, while operating profit climbed 632.1% year on year. Compared with the previous quarter, revenue climbed 31.9%, while operating profit surged 37.6%.

      • (米国)医療関連>
      • モデルナ

      At the primary …

      shi*****

      2026/10/23 18:19

      At the primary pre-specified analysis (intention-to-treat), after a median follow-up of 24.6 months, intismeran in combination with KEYTRUDA significantly reduced the risk of recurrence or death by 42% (HR=0.58 [95% CI, 0.45–0.75]; two-sided p<0.001). Intismeran plus KEYTRUDA also significantly reduced the risk of distant metastasis or death by 38% (HR=0.62 [95% CI, 0.45–0.85]; two-sided p=0.002) compared to KEYTRUDA alone. The improvements observed in RFS and DMFS were generally consistent across pre-specified patient subgroups. Overall survival (OS) data are not yet mature, but a favorable trend in OS with intismeran plus KEYTRUDA has been observed. The study remains ongoing to further evaluate OS and other key endpoints. The safety profile of intismeran plus KEYTRUDA was generally consistent with previously reported studies of the combination, and no new safety signals were observed. Based on these data, we are engaging with regulatory authorities. The efficacy of the intismeran immunization plus KEYTRUDA in the first six months was comparable with KEYTRUDA alone for risk of recurrence or death (HR=0.99 [95% CI, 0.66–1.49]) and risk of distant metastasis or death (HR=1.01 [95% CI, 0.58–1.79]). At six months, following the intismeran immunization regimen, a pre-specified sensitivity analysis of the primary endpoint showed the addition of intismeran plus KEYTRUDA reduced the risk of recurrence or death by 58% (HR=0.42 [95% CI, 0.30–0.58]) and reduced the risk of distant metastasis or death by half (HR=0.50 [95% CI, 0.34–0.73]) compared to KEYTRUDA alone. In a pre-specified sensitivity analysis of the modified intent-to-treat (mITT) population, which excluded participants who did not receive at least one dose of intismeran or placebo as planned, intismeran plus KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.51 [95% CI, 0.39–0.67]) and the risk of distant metastasis or death by 45% (HR=0.55 [95% CI, 0.40–0.77]) compared to KEYTRUDA alone.

    最近見たスレッド

    1. (株)スリー・ディー・マトリックス【7…
    2. GX MSCIガバナンス・クオリティ-…
    3. (株)バローホールディングス【9956】
    4. (株)アクリート【4395】
    5. MAXIS 米国株式(S&P500)上…

    新着スレッド

    1. 楽天・日本株3.8倍ベアIV
    2. エヌビディア
    3. アンソロピック
    4. ネビウス・グループ
    5. USDJPY

  • Yahoo!ファイナンス
  • Yahoo! JAPAN
  • プライバシーポリシー
  • プライバシーセンター
  • 利用規約
  • ヘルプ・お問い合わせ
  • JASRAC許諾番号:9008249113Y38200

    © LY Corporation

    エラーが発生しました。時間をあけて再度お試しください。

    一覧を見る

    戻る